Section Arrow
IMNM.NASDAQ
- Immunome
Quotes are at least 15-min delayed:2026/02/23 19:04 EST
After Hours
Last
 22.5
+0.7 (+3.21%)
Bid
21.5
Ask
22.5
High 22.5 
Low 21.38 
Volume 15.82K 
Regular Hours (Closed)
Last
 21.8
+0.3 (+1.40%)
Day High 
22.52 
Prev. Close
21.5 
1-M High
27.65 
Volume 
1.15M 
Bid
21.5
Ask
22.5
Day Low
21.215 
Open
21.59 
1-M Low
21.32 
Market Cap 
2.37B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 23.06 
20-SMA 24.28 
50-SMA 22.53 
52-W High 27.65 
52-W Low 5.1501 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.96/-2.20
Enterprise Value
2.38B
Balance Sheet
Book Value Per Share
2.39
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
9.04M
Operating Revenue Per Share
0.06
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
GOSSGossamer Bio0.42055-1.70945-80.26%-- 
After Hours 0.4042 -0.01635 -3.89%
IBRXImmunityBio9.82+1.12+12.87%-- 
After Hours 9.83 +0.01 +0.10%
VNDAVanda Pharmaceuticals8.17+2.41+41.84%-- 
After Hours 8.2816 +0.1116 +1.37%
IKTInhibikase Therapeutics1.8+0.04+2.27%3.74PE
After Hours 1.82 +0.02 +1.11%
KLTOKlotho Neurosciences Inc0.41+0.1573+62.25%-- 
After Hours 0.38 -0.03 -7.32%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.